New Jer­sey biotech plans for tiny IPO; Vir gets $10M Gates Foun­da­tion grant for HIV vac­cine

Chro­mo­cell Ther­a­peu­tics, based in North Brunswick, New Jer­sey, plans to go pub­lic, ac­cord­ing to an SEC fil­ing.

Ac­cord­ing to its LinkedIn, Chro­mo­cell works in drug dis­cov­ery as well as fla­vor de­vel­op­ment. Years ago, the biotech li­censed out a pain can­di­date to Astel­las for $15 mil­lion up­front. — Lei Lei Wu

This sec­tion was cor­rect­ed to re­move an in­ac­cu­rate ref­er­ence to the SEC fil­ing of how much Chro­mo­cell will raise from its IPO.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER